Media headlines about Novo Nordisk A/S (NYSE:NVO) have trended somewhat positive on Monday, Accern Sentiment reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Novo Nordisk A/S earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 47.7501224998509 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several research analysts have recently issued reports on the company. BidaskClub upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research note on Thursday, June 15th. Zacks Investment Research upgraded Novo Nordisk A/S from a “hold” rating to a “buy” rating and set a $49.00 price objective for the company in a research note on Wednesday, June 21st. Finally, TheStreet upgraded Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research note on Tuesday, May 2nd. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $53.00.

Shares of Novo Nordisk A/S (NYSE NVO) traded down 1.05% on Monday, reaching $45.33. The company had a trading volume of 1,340,341 shares. The company’s 50-day moving average price is $42.78 and its 200 day moving average price is $38.94. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $47.98. The firm has a market capitalization of $112.43 billion, a P/E ratio of 18.54 and a beta of 0.63.

The business also recently disclosed an annual dividend, which will be paid on Tuesday, August 29th. Shareholders of record on Monday, August 21st will be given a dividend of $0.336 per share. This represents a yield of 1.07%. This is a boost from Novo Nordisk A/S’s previous annual dividend of $0.33. The ex-dividend date is Friday, August 18th. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 36.00%.

ILLEGAL ACTIVITY WARNING: This piece of content was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of US & international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/novo-nordisk-as-nvo-earning-somewhat-favorable-press-coverage-study-finds/1487949.html.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Insider Buying and Selling by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.